Tony Berberabe


Pembrolizumab/Axitinib Combo Demonstrates Long-Term OS Benefit in Clear Cell RCC

September 16th 2021

Patients with clear cell renal cell carcinoma who received the combination of pembrolizumab and axitinib over sunitinib showed a benefit in adjusted overall survival and type and timing of subsequent therapy in a second interim analysis of the phase 3 KEYNOTE-426 study.

Frontline Pemigatinib Under Investigation in Advanced FGFR2+ Cholangiocarcinoma

July 2nd 2021

Single-agent pemigatinib is being compared with gemcitabine plus cisplatin in patients with unresectable and/or metastatic cholangiocarcinoma whose tumor harbor FGFR2 fusions or rearrangements in the ongoing, phase 3 FIGHT-302 trial.

Talquetamab at RP2D Elicits High Clinical Response Rate in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.

Postoperative Radiotherapy Can Be Omitted Without Impacting Metastatic Risk in Low-Grade Breast Cancer

December 10th 2020

December 9, 2020 - Whole breast irradiation, following breast-conserving surgery and adjuvant endocrine therapy, can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.

Neoadjuvant Apalutamide May Shrink Prostate Tumors

July 8th 2020

Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to undergo radical prostatectomy.

Expert Calls for More Research in Checkpoint Blockade for Upper Tract Urothelial Cancers

December 21st 2015

Compelling evidence has been presented about the various checkpoint inhibitors in bladder cancer, but, additionally there have been some provocative papers looking at genomic sequencing of upper tract compared with bladder that shows certain differences